KRAS (G12D), Isoform A, His-Tag, GDP-Loaded Recombinant

RAS mutations are responsible for more than 30% of human cancers. KRAS (G12D) is one of the KRAS mutations that is found frequently in pancreatic and colon cancers. Recent studies have led to the discovery of a small molecule called MRTX-1133 able to lock KRAS conformation in the inactive GDP-bound state, thereby blocking the KRAS (G12D) -mediated signaling pathway. Compounds that affect the nucleotide exchange (GDP to GTP) reaction in KRAS may inhibit tumor cell growth in KRAS (G12D) -driven tumors. Further studies into KRAS (G12D) mode of action and specific inhibitors will open new avenues in cancer therapy.